Telomir Pharmaceuticals Inc. has announced preclinical results for its lead candidate, Telomir-1, in a study involving PC3 human prostate cancer cells. The study demonstrated that Telomir-1 effectively reverses epigenetic silencing by DNA methylation of the STAT1 gene, a key tumor suppressor and immune response regulator. Compared to Paclitaxel and Rapamycin, Telomir-1 showed stronger epigenetic effects in aggressive prostate cancer models. The company is conducting further research to evaluate Telomir-1 across various therapeutic areas, including oncology, Wilson's disease, and age-related macular degeneration, with plans to announce its initial IND indication at a future date. These findings were reported on July 17, 2025, indicating that the results have already been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.